

INNOVATION BEYOND IMAGINATION

Chugai ESG Meeting

June 18, 2019

CHUGAI PHARMACEUTICAL CO., LTD. Representative Director, Deputy Chairman In charge of Sustainability Dept., Audit Dept.

Motoo Ueno

Important Reminders



This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.

Information regarding pharmaceuticals (including products under development) is included in this presentation, but is not intended as advertising or medical advice.

Outline of the Presentation



Chugai ESG Meeting 2019

Chugai's Value Creation

IBI 21 and ESG Initiatives


Looking Ahead

Chugai's Value Creation

A Steadfast Commitment Since Our Founding



Since the Company's founding, Chugai has maintained a dedication to working for the benefit of patients and human health, while changing its business model in response to the changing expectations and needs of society and patients.



Mission Statement



Mission

Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world

Core Values

1. Patient Centric

Make each patient's wellbeing our highest priority

2. Pioneering Spirit

Pursue innovation by improving ourselves and thinking differently


3. Integrity

Maintain the highest standards in all we do to create shared value with society

Envisioned Future

Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche


Background of Formulation of the Basic Policy



Basic Policy (Envisioned Future)




Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche



Creation of Shared Value with Stakeholders






Process for Establishing Material Issues



We analyzed the future market environment, referred to the SDGs, GRI, SASB and other frameworks, and comprehensively identified the issues that society expects Chugai to address. We also scrutinized items for which Chugai is not sufficiently meeting expectations. After an objective analysis that incorporated outside views, we narrowed the list of issues to those for realizing Chugai's Envisioned Future. Based on that process, we specified 25 material issues in eight categories.



Material Issues



 Corporate governance Risk management Compliance Disclosure and engagement Code of conduct Employee job satisfaction Human rights Climate change countermeas Use of renewable/recycled reading 	products
 Fair transactions Supply chain management Improvement of occupational safety Social contribution activities Protection of biodiversity Environmental management set 	Diversity and inclusionFair pricing

Chugai's impact on the economy, society and environment

IBI 21 and ESG Initiatives

Overview of Mid-term Business Plan IBI 21



Accelerate corporate and social development through innovation focused on innovative products



Strategy 5: Strengthen Sustainable Platforms



Corporate Value = Economic Value + Social Value



Strategy 5: Strengthen Sustainable Platforms ①



Quality management

- Maintain and enhance world-class level of quality
- Foster and instill a quality culture



Supply chain management

- Strengthen supplier management (human rights, consideration for the environment, etc.)
- Conduct supplier due diligence





Contribute to global health



Strategy 5: Strengthen Sustainable Platforms ②



Social contribution

 Contribute to medical care, welfare, social inclusion, support for the next generation, and communities



Global environment

- Implement measures to combat climate change
- Use recycled/renewable resources
- Contribute to protection of biodiversity
- Take measures to preserve water resources and mitigate water risk



Stakeholder engagement

- Promote engagement with stakeholders
- Strengthen information disclosure and dissemination



Supply Chain Management: Main Points



In addition to ensuring stable supplies and preserving quality, changes in society and the environment make it essential for management to enhance social value with suppliers.

We have strengthened our supplier evaluation to help realize sustainable supply chain management that supports continuous innovation and creation of a sustainable society.

Establishment of a Comprehensive Evaluation System for Suppliers



* EHS & compliance: Supplier's responsibility in ethics, labor, health and safety, and the environment (including child labor, forced labor and other human rights issues)

Supplier EHS & Compliance Evaluation



Dec. 2017	Began anti-corruption due diligence
Sep. 2018	Conducted dialogues with experts on human rights policy
Nov. 2018	Joined the Pharmaceutical Supply Chain Initiative (PSCI)
Jan. 2019	Formulated and announced our human rights policy
2019~	Plan to begin evaluation of supplier EHS & compliance

2021 Goals	Proposed 2030 Goal
Conduct evaluations of contract manufacturers of APIs, intermediates and formulations	Conduct evaluations of secondary suppliers of major suppliers



Global Environment: Overview of Strategy



Based on the requirements of the Paris Agreement, we examined priority issues in the value chain overall, and set next-fiscal year environmental goals for the following items in 2019.

We are beginning to consider measures for CDP evaluation improvements and initiatives consistent with TCFD recommendations.


Priority Themes in Mid-term Business Plan	Items		2020 KPIs	Considering as 2025-2030 KPIs
	F	1	20% reduction (GJ per employee)	•
	Energy consumption	V	Avg. fuel efficiency of MR fleet: 16 km/L or higher	•
Climate change countermeasures	CO ₂ emissions	1	<u> </u>	•
(Prevention of global	Renewable energy usage rate	\checkmark	—	•
warming)	Use of CFCs	\checkmark	Prohibition of use of controlled CFCs	•
	Scope 3 (flight, waste, etc.)	\checkmark		•
	Waste recycling ratio	\checkmark	99% or higher at 3 or more sites	
Resource conservation/	Volume of waste generated	1	<u> </u>	•
Waste management	Water consumption	\checkmark		•
	Water recycling ratio	\checkmark	—	•
	Prevention of pollution (air, water)	\checkmark	Environmental impact assessment (WET testing)	•
Biodiversity protection	Chemical substance management	\checkmark	<u> </u>	•
(Reduction of environmental impact)	Environmental impact assessment		<u> </u>	•
i í	Ecological footprint			•
EHS management	External assurance of non-financial information		—	•
system	Supply chain management		—	
	Training, internal/external audits	\checkmark		—

Items reported to Roche

Energy Consumption



2020 target: 20% reduction of energy consumption per employee vs. 2010 Total energy consumption in 2018 increased 11% from 2017 due to start of operation of UK3 Expect to achieve 2020 target for non-renewable energy consumption per employee by introducing electricity from renewable energy sources



Specific Initiatives: Efforts at New Research Facility



Chugai Life Science Park Yokohama

A core research facility to be built in Yokohama, Kanagawa Prefecture (planned completion in 2022) •Building area: 35,210m² •Total floor area: 119,960m²

Emphasizing climate change measures, local disaster preparedness, and biodiversity preservation; aiming to acquire LEED Gold certification for environmental performance

Including consolidation of existing facilities, will reduce our overall environmental footprint

Sign environmental agreement with city of Yokohama, emphasizing coexistence with the local community




Aiming for LEED Certification

We are emphasizing climate change measures, local disaster preparedness and protection of biodiversity by introducing green infrastructure, and are aiming to acquire LEED Gold certification.



Smaller Ecological Impact

We plan to reduce our overall energy use, CO₂ emissions and waste by closing the Gotemba and Kamakura research centers and consolidating their functions and facilities.



Coexistence

Emphasizing coexistence with the local community and environment, we plan to create a park and recreation spot on the premises and cooperate with educational institutions.



Human Resource Initiatives: Main Points



Talent management	 Introduced a talent management system in 2012, and implemented it while making modifications as necessary Globally unified competencies used in evaluation as the basis of talent management Built CAPTAIN, a backbone system for HR management, and created a central database Based on these, created development plans for each employee, and applied them in talent development Built a talent pool for selection and visualization of successor candidates for 94 positions Will further review our HR requirements and development system to speed up recruiting, development and placement of world-class talent
Diversity & inclusion (D&I)	 Launched a working team in 2010 and set up specialized D&I unit in 2012 Focused on work environment improvements and career planning and development measures for female employees Conducted diversity management training for managers Ratio of female managers 2018 target: 13% or higher, Actual: 13.3% 2021 target: 16% or higher Updated HR systems and conducted training to promote inclusion of older and foreign employees Drew up and will implement a detailed roadmap to foster an inclusive workplace culture where diverse employees can excel and pursue innovation
Employee health management	 Established a company-wide health and safety promotion framework to pursue both individual and organizational health Established and implemented measures to support employees with cancer, prevent/treat lifestyle diseases, promote employees' mental health, address presentism, improve health literacy, and promote workplace safety


Human Resource Initiatives: D&I Roadmap



		2019		2020	2021	KPI	
Fostering an organizational culture that generates innovation and is accepting of failure	5	 Identify issues for fostering a c that generates innovation Study measures and implement trial basis 		 Review trials and fully introduce measures Identify and present innovation stories 	Employee Survey Reinforce behavior that generates innovation 	All-employee survey Rate of affirmative answers to innovation questions 80% or higher	IBI21 Target Outcome
		 Identify issues for improving engagement Study measures and implement a trial basis 	nt on	Review trials and fully introduce measures	 Increase opportunities for employee growth and taking on challenges 	All-employee survey	
Improving engagement of				Chugai Group and provide training oppo nancing management capabilities	rtunities	Rate of affirmative answers to questions on engagement and	Innovation stories that leverage the
diverse talent (improving engagement through work style reform)		 Study and implement measures for changing mindset and behaviors Identify issues for bus process reform 	5	 Implement measures for business process reform Promote work style reform by sharing best practices 	 Work continuously to establish work style reform 	stimulating workplace environment 80% or higher* * KPI set above the average for global	strengths of diversity and inclusion
		Review and enhance	systems,	mechanisms, tools, workspaces, etc.		companies	
Proactively appointing and deploying women and people from different cultures and backgrounds to		 Create a system of divisional commitment to the success of Identify issues, and study and implement measures to encout the promotion of women 		• Enhance approach to managers and employees to encourage the promotion of women	• Further expand the number of female leader candidates	Ratio of female managers 16% or higher	
take on business challenges		Actively recruit, retain and creat	ite opportu	nities for promotion for people from diffe	erent cultures and backgrounds	(also set 3 other KPIs)	

Human Resource Initiatives: Employee Survey





Evaluation Item

- I understand why it is necessary to achieve the targets of ACCEL 15/IBI 18 (Understanding)
- I am doing what I must to carry out ACCEL 15/IBI 18 (Action)
- My workplace has started to change for the better due to activities for ACCEL 15/IBI 18 (Realization)

Note: This survey was not conducted in 2017.

Overview of Employee Survey (2018)	
Participants and response rate	Participants: 6,994 (6,498 in Japan, 496 overseas) Respondents: 6,806 (6,321 in Japan, 485 overseas) Response rate: 97.3%
Question categories	Employee engagement, environment for utilizing employees, strategy and direction, leadership, quality and customer orientation, respect for individuals, opportunities for growth, compensation and benefits, performance indicators, authority and discretion, resources, education and training, framework for collaboration, business processes and organizational structure, and innovation
Benchmark data	Average results from global companies, leading companies, pharmaceutical companies and Japanese companies

Survey Results (Overall Trends)

- In all question categories, Chugai scored above the average for Japanese companies. In Japan, Chugai is a leader in terms of employee awareness.
- Chugai is on par with global companies. Employee engagement is on par with top global companies.
- Issues for further improvement are the environment for utilizing employees, as well as the resources, framework for collaboration, and business processes and organizational structure that underlie that environment.
- The percentage of employees who gave employee engagement and working environment high marks is at the level of global companies.


Corporate Governance




Alliance Arrangement with Roche

- Roche acquires majority of Chugai's shares (50.1%*)
- Chugai maintains management independence (TSE listing)

*Roche has owned 59.9% of Chugai's shares since 2008




Composition of the Board of Directors



Corporate Governance Topics ①



Evaluation of Effectiveness of Board of Directors



Status of Improvements Identified through Evaluation of the Effectiveness of the Board of Directors

		Main Items for Improvement	Main New Initiatives Implemented after Analysis and Evaluation
2	2016	 Review structure of self-evaluation survey and answer options Assiduously provide materials for Board of Directors meetings at least four business days prior to the event Enhance content of reports provided to Board of Directors and make materials easily understood 	 Began providing information on industry environment trends and other information to outside directors in a Chairman's Message at the beginning of the Board of Directors meetings Provided Board of Directors meeting schedule for the coming year at an early date Implemented factory tours
2	2017	 Change the procedure for providing materials to outside officers Enhance topics for reports to the Board of Directors 	 Held lectures (information on trends of general shareholders meetings) by external experts (attorneys)
2	2018	 Conduct prior and additional explanations on agenda items with complex content such as governance and legal matters 	 Issued the Chugai IR Activities Report to outside officers (every quarter) Provided a glossary of technical terms, abbreviations etc. to outside officers

Corporate Governance Topics ②





CIC Chair

 Henry L. Nordhoff (U.S.) Former Chairman of the Board, Gen-Probe, Inc.

CIC Members

- Virginia Bottomley (U.K.) Former Health Secretary of the U.K.
- William M. Burns (U.K.) Former Chief Executive Officer of the Pharmaceuticals Division, F. Hoffmann-La Roche Ltd

- Andrew von Eschenbach (U.S.) Former Commissioner of the U.S. Food and Drug Administration
- Victor Halberstadt (Netherlands) Professor, Leiden University
- Andre Hoffmann (Switzerland)
 Vice Chairman, Roche Holding Ltd.
- Franz B. Humer (Switzerland)
 Former Chairman, Diageo plc
 Former Chairman, Roche Holding Ltd.

- Robert A. Ingram (U.S.) Former Vice Chairman of Pharmaceuticals, GlaxoSmithKline plc
- Arnold J. Levine (U.S.) Professor Emeritus at the Institute for Advanced Study, Princeton University Discoverer of the p53 cancer suppressor protein
- Sonosuke Kadonaga (Japan) President, Intrinsics

Looking Ahead

Initiatives for the SDGs





Goal 3

Provision of innovative drugs and services/Provision of solutions for patients/ Contribution to global health

Goal 8	Improvement of occupational health and safety/Talent management/Promotion of work- life synergy (promotion of use of childcare leave system by male employees and telecommuting system, etc.)/Supply chain management
Goal 9	Provision of innovative drugs and services/Initiatives for personalized healthcare/Establishment of open innovation networks with academia and other parties
Goal 12	Ensuring stable supply and stable inventories/Strengthening of quality assurance and stable supply/Use of renewable and recyclable resources/Environmental management
Goal 17	Establishment of open innovation networks/Stakeholder engagement strategy/Participation in GHIT Fund and Access Accelerated

Looking Ahead




Creation of Shared Value with Society Realization of advanced and sustainable patient-centric healthcare



PSCI (Pharmaceutical Supply Chain Initiative)



The PSCI is a non-profit organization established to improve sustainability among suppliers, buyers and society through standardization of guidelines for responsible procurement by pharmaceutical companies and creation of an information sharing platform for buyers.



Activities with ESG Investment in Mind



- Reselection as Component of DJSI Asia Pacific Index -

Chugai is included in all ESG indices adopted by GPIF



Chugai continues to be selected for inclusion in global socially responsible investment indices



FTSE4Good

Dow Jones Sustainability Indices


Chugai was selected for the fourth time as a component of the DJSI Asia Pacific Index, a socially responsible investment index

Stock Performance (From 2002)



- Relative change in stock price based on 9/30/2002 value fixed at 100 -

From 2017 onwards, stock prices are steadily rising mainly due to expectations for Hemlibra



Contacts: Corporate Communications Dept.

Tel:	+81 (0) 3-3273-0881
E-mail:	pr@chugai-pharm.co.jp
	Shimizu, Hiroshi Araki, Chisato Miyoshi, nada, Shumpei Yokoyama

Tel: : +81 (0)3-3273-0554

E-mail: ir@chugai-pharm.co.jp

Toshiya Sasai, Takayuki Sakurai, Tomoyuki Shimamura, Sachiyo Yoshimura